Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
European Journal of Rheumatology|January 18, 2023
The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life DatabaseNilüfer Alpay Kanıtez, Sedat Kiraz, Ediz Dalkılıç, et al.
Clinical and Experimental Rheumatology|June 29, 2022
Clinical and laboratory factors associated with bamboo spine in patients with axial spondyloarthritis: are there clues for bamboo spine?Pamir Atagündüz, Sedat Kiraz, Servet Akar, et al.
Turkish Journal of Medical Sciences|February 21, 2021
Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemicUmut Kalyoncu, Yavuz Pehlivan, Servet Akar, et al.
Archives of Rheumatology|December 4, 2023
Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure databaseEmine Duygu Ersözlü, Mustafa Ekici, Belkis Nihan Coşkun, et al.
European Journal of Rheumatology|January 11, 2020
Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registrySibel Zehra Aydın, Gezmiş Kimyon, Cem Özişler, et al.
Rheumatology International|July 6, 2021
In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?Burcu Yagiz, Belkis Nihan Coskun, Yavuz Pehlivan, et al.
Rheumatology (Oxford, England)|October 31, 2016
The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patientsUmut Kalyoncu, Özün Bayindir, Mustafa Ferhat Öksüz, et al.
International Journal of Rheumatic Diseases|May 13, 2025
Real-World Insights From Türkiye: Biologic DMARDs Usage in Spondyloarthritis Patients With Chronic Kidney DiseaseDilara Bulut Gökten, Mehmet Engin Tezcan, Burcu Yağız, et al.
Pageof 4